Development of Flow Injection Analysis Method for the Second-Tier Estimation of Succinylacetone in Dried Blood Spot of Newborn Screening
- PMID:35125692
- PMCID: PMC8799791
- DOI: 10.1007/s12291-020-00944-z
Development of Flow Injection Analysis Method for the Second-Tier Estimation of Succinylacetone in Dried Blood Spot of Newborn Screening
Abstract
Tyrosinemia type 1 (TYR1) is a devastating aminoacidopathy, leading to mortality without medical intervention. Although, detection and quantification of tyrosine in dried blood spot (DBS) is possible, but being a non-specific marker for TYR1 and its frequent association with transient neonatal tyrosinemia limits its applicability. Despite, Succinylacetone (SUAC) being a pathognomonic marker for TYR1, but not often detectable by routine newborn screening (NBS). We envisaged to determine SUAC in DBS by an in-house flow injection analysis method on a liquid chromatography/tandem mass spectrometry (LC-MS/MS). Succinylacetone was eluted from the residual 3.2 mm DBS of primary NBS by an extraction solution containing acetonitrile-water-formic acid mixture containing stable-isotope labelled internal standard (IS) for SUAC and hydrazine. Detection and quantification was performed by the mass spectrometer using multiple reaction monitoring mode at m/z 155.1 → 109.1 for SUAC and m/z 160.1 → 114.1 for the SUAC IS. The assay was linear over a calibration range of 0.122-117.434 µmol/L. The Intra-day and Inter-day precision and accuracy for the assay was determined at two different levels of SUAC (2.542 µmol/L and 14.641 µmol/L), which showed a coefficient of variation of (6.91% and 12.65%) and (8.57% and 12.27%) respectively. The accuracy also ranged between 101.2 and 103.87%.This method provided the necessary sensitivity, precision, accuracy, recovery and linearity and hence, has the potential to reduce the false positive, false negative results which significantly minimise the cost involved in the screening and follow up of TYR1 patients.
Supplementary information: The online version of this article (10.1007/s12291-020-00944-z) contains supplementary material, which is available to authorized users.
Keywords: Fumarylacetoacetate hydrolase; Inborn errors of metabolism; Mass spectrometry; Newborn screening; Tyrosine; Tyrosinemia type 1.
© Association of Clinical Biochemists of India 2021.
Conflict of interest statement
Conflict of interestThe authors declare that they have no conflict of interest.
Figures




Similar articles
- Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I.Magera MJ, Gunawardena ND, Hahn SH, Tortorelli S, Mitchell GA, Goodman SI, Rinaldo P, Matern D.Magera MJ, et al.Mol Genet Metab. 2006 May;88(1):16-21. doi: 10.1016/j.ymgme.2005.12.005. Epub 2006 Jan 31.Mol Genet Metab. 2006.PMID:16448836
- Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots.Turgeon C, Magera MJ, Allard P, Tortorelli S, Gavrilov D, Oglesbee D, Raymond K, Rinaldo P, Matern D.Turgeon C, et al.Clin Chem. 2008 Apr;54(4):657-64. doi: 10.1373/clinchem.2007.101949. Epub 2008 Feb 15.Clin Chem. 2008.PMID:18281422
- Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs.De Jesús VR, Adam BW, Mandel D, Cuthbert CD, Matern D.De Jesús VR, et al.Mol Genet Metab. 2014 Sep-Oct;113(1-2):67-75. doi: 10.1016/j.ymgme.2014.07.010. Epub 2014 Jul 17.Mol Genet Metab. 2014.PMID:25066104Free PMC article.
- Newborn screening for Tyrosinemia type 1 using succinylacetone - a systematic review of test accuracy.Stinton C, Geppert J, Freeman K, Clarke A, Johnson S, Fraser H, Sutcliffe P, Taylor-Phillips S.Stinton C, et al.Orphanet J Rare Dis. 2017 Mar 9;12(1):48. doi: 10.1186/s13023-017-0599-z.Orphanet J Rare Dis. 2017.PMID:28274233Free PMC article.Review.
- Liquid Chromatography-Tandem Mass Spectrometry in Newborn Screening Laboratories.Gelb MH, Basheeruddin K, Burlina A, Chen HJ, Chien YH, Dizikes G, Dorley C, Giugliani R, Hietala A, Hong X, Kao SM, Khaledi H, Klug T, Kubaski F, Liao HC, Martin M, Manning A, Orsini J, Peng Y, Ranieri E, Rohrwasser A, Szabo-Fresnais N, Turgeon CT, Vaz FM, Wang LY, Matern D.Gelb MH, et al.Int J Neonatal Screen. 2022 Nov 28;8(4):62. doi: 10.3390/ijns8040062.Int J Neonatal Screen. 2022.PMID:36547379Free PMC article.Review.
References
- Vernon HJ. Inborn errors of metabolism: advances in diagnosis and therapy. JAMA Pediatr. 2015;169:778–782. - PubMed
- Almannai M, Marom R, Sutton VR. Newborn screening: a review of history, recent advancements, and future perspectives in the era of next generation sequencing. Curr Opin Pediatr. 2016;28:694–699. - PubMed
- Levy HL, Shih VE, Madigan PM, MacCready RA. Transient tyrosinemia in full-term infants. JAMA. 1969;209:249–250. - PubMed
- Mak CM, Lam C-W, Chim S, Siu T-S, Ng K-F, Tam S. Biochemical and molecular diagnosis of tyrosinemia type I with two novel FAH mutations in a Hong Kong chinese patient: recommendation for expanded newborn screening in Hong Kong. Clin Biochem. 2013;46:155–159. - PubMed
Related information
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous